OncoGenesis addresses the tremendous, unmet clinical need for an easy-to-use and accurate screening of women for cervical cancer. The company offers a comprehensive solution ranging from optimal specimen collection to point-of-care diagnostic testing, setting a new standard of care for diagnosing and treating cervical cancer worldwide. Our goal is to provide a solution that clinically outperforms existing screening technologies in a cost-effective format that can be run anywhere globally, including resource-limited regions of the world where the problem of cervical cancer is a healthcare crisis. To accomplish this, OncoGenesis has developed a useful self-collection device, iPap®, that allows women to obtain their cervical specimens in the privacy of their homes. The company is also developing the CerMark® multiplex biomarker test that measures the critical cellular changes in a cervical tissue specimen to detect cervical cancer and its progression. The CerMark test will be available first on a laboratory-based system (LAB) and then on our Point-of-Care (POC) device.